Linear Source Registry for Prostate Cancer

CivaString Registry for Prostate Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02516709

Acronym

CaRePC

Enrollment

Registered

2015-08-06

Start date

2015-06-30

Completion date

2023-06-30

Last updated

2023-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Ongoing follow up for subjects implanted with the Linear Source String for prostate cancer.

Detailed description

This registry is being conducted to provide long term analysis on the use of the linear Civastring source for prostate cancer. Prospective data collection will record and demonstrate biochemical response rates. Long term side effects and adverse events will be monitored.

Interventions

RADIATIONLinear LDR Source

The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years old * Plans to remain in care of enrolling physician for 5 years * \> 5 years life expectancy * Signed informed consent * Enrolled within 6 weeks of implant or within 365 days of prior implant

Exclusion criteria

* Not willing or able to comply with protocol visit schedule

Design outcomes

Primary

Measure	Time frame
Biochemical Response Rate (PSA)	Up to 5 years

Secondary

Measure	Time frame
Side Effects (IPSS, IIEF, RFAS score)	Up to 5 years
Adverse Events	Up to 5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026